Success and Complication Rates of Transvenous Lead Extraction in a Developing High-Volume Extraction Center: The Zurich Experience
- PMID: 36983262
- PMCID: PMC10051593
- DOI: 10.3390/jcm12062260
Success and Complication Rates of Transvenous Lead Extraction in a Developing High-Volume Extraction Center: The Zurich Experience
Abstract
Introduction: Transvenous lead extractions are increasingly performed for malfunction or infection of cardiac implantable electronic devices, but they harvest a potential for complications and suboptimal success. Apart from multicenter registries and reports from highly experienced single centers, the outcome in individual newly developing high-volume centers starting a lead extraction program is less well established. We aimed to evaluate the clinical and radiological success and complication rate at our center, having started a lead extraction program less than a decade ago.
Methods: We retrospectively analyzed patients who underwent transvenous lead extraction at the University Hospital Zurich from 2013 to 2021 regarding success as well as complications and compared our results to previously reported outcome rates.
Results: A total of 346 patients underwent 350 transvenous lead extractions from January 2013 to December 2021. Combined radiological success was achieved in 97.7% and clinical success in 96.0% of interventions. Procedure-related major complications occurred in 13 patients (3.7%). Death within 30 days after transvenous lead extractions occurred in 13 patients (3.7%), with a procedure-related mortality of 1.4% (five patients).
Summary: Transvenous lead extractions in newly developing high-volume centers can be performed with high clinical and radiological success rates, but procedure-related major complications may affect a relevant number of patients. Compared to large single or multicenter registries of experienced centers, the success rate may be lower and the complication rate higher in centers newly starting with lead extraction, which may have important implications for patient selection, procedural planning, proctoring, and safety measures.
Keywords: complication; lead extraction; outcome; single center; success.
Conflict of interest statement
Daniel Hofer reports educational grants, consultant or speaker fees, and fellowship support from Abbott, Medtronic, Biotronik, Boston Scientific, Biosense Webster, Novartis, Bayer, Pfizer, and Spectranetics. Alexander Breitenstein has received consultant and/or speaker fees from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, Bristol-Myers Squibb, Cook Medical, Daiichi Sankyo, Medtronic, Pfizer, and Spectranetics/Philipps. Jan Steffel has received consultant and/or speaker fees from Abbott, Alexion, Astra-Zeneca, Bayer, Berlin-Chemie, Biosense Webster, Biotronik, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Medscape, Medtronic, Menarini, Merck/MSD, Organon, Pfizer, Saja, Servier, andWebMD. He reports ownership of CorXL and Swiss EP. Steffel has received grant support through his former institution from Abbott, Bayer Healthcare, BiosenseWebster, Biotronik, Boston Scientific, Daiichi Sankyo, and Medtronic. Sasse reports educational grants from Biotronik.
Figures
References
-
- Diemberger I., Biffi M., Martignani C., Boriani G. From lead management to implanted patient management: Indications to lead extraction in pacemaker and cardioverter-defibrillator systems. [(accessed on 27 February 2023)];Expert Rev. Med. Devices. 2011 8:235–255. Available online: https://pubmed.ncbi.nlm.nih.gov/21381913/ - PubMed
-
- Bongiorni M.G., di Cori A., Segreti L., Zucchelli G., Viani S., Paperini L., Menichetti F., Coluccia G., Soldati E. Where is the future of cardiac lead extraction heading? [(accessed on 27 February 2023)];Expert Rev Cardiovasc. 2016 14:1197–1203. Available online: https://pubmed.ncbi.nlm.nih.gov/27494362/ - PubMed
-
- Hauser R.G., Katsiyiannis W.T., Gornick C.C., Almquist A.K., Kallinen L.M. Deaths and cardiovascular injuries due to device-assisted implantable cardioverter-defibrillator and pacemaker lead extraction. [(accessed on 27 February 2023)];Europace. 2010 12:395–401. doi: 10.1093/europace/eup375. Available online: https://pubmed.ncbi.nlm.nih.gov/19946113/ - DOI - PMC - PubMed
-
- Kurtz S.M., Ochoa J.A., Lau E., Shkolnikov Y., Pavri B.B., Frisch D., Greenspon A.J. Implantation trends and patient profiles for pacemakers and implantable cardioverter defibrillators in the United States: 1993–2006. [(accessed on 27 February 2023)];Pacing Clin. Electrophysiol. 2010 33:705–711. doi: 10.1111/j.1540-8159.2009.02670.x. Available online: https://pubmed.ncbi.nlm.nih.gov/20059714/ - DOI - PubMed
-
- Wazni O., Epstein L.M., Carrillo R.G., Love C., Adler S.W., Riggio D.W., Shahzad S.K., Bashir J., Greenspon A.J., DiMarco J.P., et al. Lead extraction in the contemporary setting: The LExICon study: An observational retrospective study of consecutive laser lead extractions. [(accessed on 27 February 2023)];J. Am. Coll. Cardiol. 2010 55:579–586. doi: 10.1016/j.jacc.2009.08.070. Available online: https://pubmed.ncbi.nlm.nih.gov/20152562/ - DOI - PubMed
LinkOut - more resources
Full Text Sources
